01 / ATLAS
What it is
GHK-Cu is the complex of the tripeptide glycyl–histidyl–lysine with a copper ion. This entry covers skin and extracellular matrix research. [1]
02 / ATLAS
How it works
Fibroblast experiments investigated changes in collagen synthesis. These cells produce components of the matrix supporting tissues. [1]
03 / ATLAS
What research shows
Laboratory findings support interest in skin repair and aging. Effects measured in cells do not automatically demonstrate a visible benefit in people. [1]
A 2023 study tested GHK-Cu with hyaluronic acid. Findings for that formulation cannot automatically be applied to GHK-Cu alone. [2]
04 / ATLAS
Study data
Maquart et al., 1988: fibroblast cultures, measuring collagen synthesis. [1]
Jiang et al., 2023: cell and ex vivo skin tests examining the GHK-Cu–hyaluronic acid combination and collagen IV. This was not a clinical efficacy trial of injections. [2]
05 / ATLAS
Safety and observed adverse reactions
The FDA notes limited human data and potential immune-response and impurity risks for injectable forms. [3]
Data on a topical formulation do not establish the safety of the same molecule given by another route.
06 / ATLAS
Research status
The selected evidence is preclinical. Cosmetic use and investigation as a treatment are different contexts; this entry does not establish an administration protocol.
07 / REFERENCES
Studies and sources
- Maquart et al. · Collagen synthesis in fibroblasts (1988) ↗Original research · in vitro
- Jiang et al. · GHK-Cu and hyaluronic acid (2023) ↗Original research · cells and ex vivo skin
- FDA · Safety information for injectable GHK-Cu ↗Official assessment · United States


